Current cell-based methodologies to characterize biologics targeting interleukins include proliferation or cytokine release assays which require the use of primary cells. These primary cells introduce challenges with their inherent donor-to-donor variability and lack of specificity. To address these challenges, Eurofins DiscoverX offers services for a growing menu of cell-based assays for interleukins that are highly specific and can be used to screen anti-ligand or anti-receptor antibodies and enable rapid development of drugs targeting immune-system disorders.
Use the ILscan Services During:
- Early discovery and screening
Advantages of ILscan Services
- Discover novel new ligands
- Screen anti-ligand and anti-receptor antibodies for most interleukin assays
- Determine potencies of novel molecules
- Identify the best candidates for therapeutic development with an assay that resembles in vivo biology
